Note: Selected releases translated to English. To see all Nasdaq regulatory releases, see Swedish press releases.
On the 19th of March 2019, an Extraordinary General Meeting in ExpreS2ion Biotech Holding AB was held. Below is a summary of the decisions that were taken. All decisions were taken with required majority.
ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") will participate at several key events in March and April, including ISBiotech, March 4-6, in Norfolk, VA, USA, Sedermeradagen, March 12, In Copenhagen, Denmark, and World Vaccine Congress, April 15-17, in Washington, DC, USA.
The shareholders of ExpreS2ion Biotech Holding AB, 559033-3729, are hereby invited to attend an Extraordinary General Meeting on Tuesday, March 19, 2019, at 10.00 at c/o Mazars SET, Terminalgatan 1, in Helsingborg.
ExpreS2ion Biotech Holding AB (“ExpreS2ion”) today announces that the Company is conducting a directed share issue to a number of existing shareholders and strategic investors of initially approx. SEK 8 million, with attached consideration-free warrants, which in later stages can provide the Company with a further approx. SEK 9.6 million. The directed share issue is conducted in order to finance an accelerated pace of operations and increased investments in the business to ensure long-term good development. The motive to deviate from the shareholders' preferential rights is that considers it beneficial for the Company and the shareholders to strengthen the owner base partly by broadening the base of major shareholders, and partly by enabling share ownership for new strategic investors with special interest in the Company, and to avail of the opportunity to add new working capital to conditions attractive to the Company (especially the time and cost aspect of the implementation of the capitalisation). Through the directed share issue, the Company is supplied with working capital in order to work towards set goals, in a cost and time-efficient manner and thereby strengthen the Company's financial position. The above aspects as well as the prevailing market conditions have resulted in the conclusion that, according to the Board's opinion, there have been predominant reasons for deviating from the shareholders' preferential rights to the benefit of the Company and the shareholders in the long term. The directed share issue is subject to approval by an Extraordinary General Meeting, which is planned to be held on March 19, 2019. Notice to Extraordinary General Meeting is scheduled to be published shortly.
ExpreS2ion Biotech Holding AB (“ExpreS2ion”) hereby publishes financial report for the period of January – December 2018. The report is available as an attached document to this press release and on the Company’s website (www.expres2ionbio.com). Below is a summary of the report.
ExpreS2ion Biotech Holding AB (“ExpreS2ion”) announces that its joint venture AdaptVac ApS (“AdaptVac”) has been awarded approx. SEK 3.6 million by the Danish Innovation Foundation for its participation in a vaccine project aimed at preventing post-weaning diarrhea (PWD), a major cause of antibiotic use in the swine industry.
ExpreS2ion Biotech Holding AB and its affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announce that the placental malaria vaccine (PlacMalVac) consortium, of which ExpreS2ion is part, has announced successful phase I clinical study results. The PAMVAC vaccine, manufactured using the ExpreS2 platform, was demonstrated to be safe, well-tolerated and to elicit specific antibody responses in all participants.
ExpreS2ion Biotech Holding AB (“ExpreS2ion”) announces that its joint venture AdaptVac ApS (“AdaptVac”) has received DKK 2.2 million (SEK 3.2 million) in funding from the Danish Innovation Foundation for two new vaccine development projects: cardiovascular disease (CVD) in humans and HER2+ breast cancer in dogs. The HER2+ dog project will also be used as preclinical studies for the ongoing HER2+ human breast cancer vaccine project AV001.
ExpreS2ion Biotech Holding AB (“ExpreS2ion") announces the publication of the first visual image of the molecular ’key’ the deadliest malaria parasite uses to enter human blood cells in Nature. The publication was authored by an international team, including scientists from ExpreS2ion, led by the Walter and Eliza Hall Institute of Medical Research (“WEHI”). This breakthrough will contribute to the development of vaccines based on a patent co-owned equally by WEHI and ExpreS2ion.
ExpreS2ion Biotech Holding AB (“ExpreS2ion”) hereby publishes the financial report for the period of January – September 2018. The report is available as an attached document to this press release and on the Company’s website (www.expres2ionbio.com). Below is a summary of the report.
Horsholm, Denmark, October 31 2018 – Today, ExpreS2ion Biotech Holding AB (“ExpreS2ion”) announces that The Jenner Institute of the University of Oxford presents positive results from its Phase I/IIa clinical studies with their RH5.1 blood-stage malaria vaccine at a scientific meeting in New Orleans. The vaccine, developed and manufactured using ExpreS2ion’s ExpreS2 platform, was shown to be safe and it is the first vaccine to demonstrate a reduction in the parasite multiplication rate following a blood-stage controlled human malaria infection.
ExpreS2ion Biotech Holding AB and its affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announce that the Company will participate at several key events in October and November, including World Vaccine Congress, October 29-31, 2018, in Lisbon, Portugal, and Sedermeradagen, November 7, 2018, in Stockholm, Sweden.
Horsholm, Denmark, October 18, 2016 – Today, ExpreS2ion Biotech Holding AB (“ExpreS2ion”) announces that its collaboration partner, Jenner Institute of the University of Oxford, will present the results from the Phase I/IIa clinical studies of its RH5.1 blood stage malaria vaccine at the annual American Society of Tropical Medicine and Hygiene (ASTMH) meeting on the 31st of October in New Orleans.
ExpreS2ion Biotech Holding AB and its affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announce that a recently published scientific article in Nature Communications on the Pfs48/45 malaria vaccine candidate adds further evidence to support that the ExpreS2 platform is an excellent tool for producing transmission blocking malaria vaccines. This is a promising class of next generation vaccines, which is developed with substantial support from the Bill and Melinda Gates foundation.
ExpreS2ion Biotech Holding AB and its affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announce that its joint venture AdaptVac has received a notice of allowance in the USA for its patent application covering its novel vaccine treatment for HER2-positive breast cancer. This means that the patent is expected to be issued shortly, which is an important step forward for the project and documenting the patentability of the virus-like-particle (VLP) technology platform. After final approval, the patent will be valid at least 20 years from the priority date, 15-01-2015.
ExpreS2ion Biotech Holding AB’s fully owned subsidiary ExpreS2ion Biotechnologies ApS (“ExpreS2ion”) announces that it has amended its Research & Commercial License Agreement with U.S.-based partner and licensee Integrated BioTherapeutics (“IBT”) to include own ExpreS2-based products, initially a number of Zika virus antigens.
ExpreS2ion Biotech Holding AB (“ExpreS2ion”) hereby publishes the financial report for the period of January – June 2018. The report is available as an attached document to this press release and on the Company’s website (www.expres2ionbio.com). Below is a summary of the report.
ExpreS2ion Biotech Holding AB and its affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announce that a scientific article on the production of a malaria vaccine candidate using the Company’s ExpreS2 platform was published today in the journal npj Vaccines, a part of Nature Partner Journals Series. The article “Production, quality control, stability, and potency of cGMP-produced Plasmodium falciparum RH5.1 protein vaccine expressed in Drosophila S2 cells”, adds further documentation to the successful use of ExpreS2 as a GMP certified production platform for a product that are currently in a Phase 1/2a clinical trial.
ExpreS2ion Biotechnologies ApS (“ExpreS2ion") has appointed Bent U. Frandsen, currently VP of Business Development, as Chief Business Officer (CBO). He will manage a proactive effort to substantially increase the customer base in the Company’s vaccine development and production services segment. Furthermore, ExpreS2ion appoints Honeybadger as non-exclusive IR partner on the Swedish market.
ExpreS2ion Biotech Holding AB and its affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announce that the Company will hold presentations at an annual meeting hosted by the World Biopharm Forum in Oxford, UK, June 20-22 and at the Vaccine Technology VII Meeting in Mont Tremblant, Quebec, Canada, June 17-22.
ExpreS2ion Biotech Holding AB’s fully owned subsidiary ExpreS2ion Biotechnologies ApS (“ExpreS2ion”) has signed a collaboration agreement regarding vaccine development and GMP (Good Manufacturing Practice) manufacturing with its Portuguese partner GenIbet Biopharmaceuticals, S.A. (“GenIbet”). The agreement strengthens ExpreS2ion’s position as a full-service provider from discovery up to early clinical development.
Today, May 24th, 2018, the annual general meeting of ExpreS2ion Biotech Holding AB (publ) was held. A summary of the decisions that were made follows below. All decisions were taken with required majority.
ExpreS2ion Biotech Holding AB and its affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announce that the Company’s patent application “Improved Protein Expression System”, that covers the entire ExpreS2 platform, has been allowed in Canada and will be granted with expiry June 12, 2029.
ExpreS2ion Biotech Holding AB (“ExpreS2ion”) hereby publishes financial report the period of January – March 2018. The report is available as an attached document to this press release and on the Company’s website (www.expres2ionbio.com). Below is a summary of the report.
The Board of Directors and the Chief Executive Officer of ExpreS2ion Biotech Holding AB hereby publishes the Annual Report for the fiscal year 2017. The Annual Report and the accompanying Auditor’s Report is available on the Company’s website (www.expres2ionbio.com).
ExpreS2ion Biotech Holding AB’s fully owned subsidiary ExpreS2ion Biotechnologies ApS (“ExpreS2ion”) announces that its U.S.-based partner and licensee Integrated BioTherapeutics (“IBT”) has initiated sales and marketing of its first ExpreS2-based product. The product, an Ebola virus glycoprotein, is marketed as a part of IBT’s high-quality research protein portfolio and can be used in the development of diagnostic or therapeutic products.
In February 2018, ExpreS2ion Biotech Holding AB (“ExpreS2ion”) conducted a rights issue of shares in which the public also were given the opportunity to subscribe for shares. Through the rights issue, 2,400,403 shares were issued. Last day of trading in BTAs (paid subscription share) is March 15th, 2018 and stop date is March 19th, 2018.
Hørsholm, Denmark, March 2nd, 2018 – ExpreS2ion Biotech Holding AB (“ExpreS2ion”) today announces that the Company’s rights issue of approximately SEK 19.2 million in order to finance investments in several parts of the core business and also to supply additional working capital for future investments in new business opportunities for both ExpreS2ion and AdaptVac, has been oversubscribed. The rights issue was subscribed to approximately SEK 30.3 million, corresponding to a subscription rate of approximately 158 percent. Through the rights issue, a total of 2,400,403 shares are issued and ExpreS2ion is provided approximately SEK 19.2 million before issuing costs. The issuing costs are calculated to amount to approximately SEK 1.3 million. Contract notes are planned to be sent out today, March 2nd, 2018.
Today, on February 8th, 2018, the subscription period in ExpreS2ion Biotech Holding AB’s (“ExpreS2ion”) rights issue, starts. The rights issue is also open to the public. The subscription period ends on February 27th, 2018. A fully subscribed rights issue provides ExpreS2ion with approximately SEK 19.2 million before issuing costs. Beforehand, the company has agreed on subscription commitments amounting to approximately SEK 10.9 million, which equals about 57 % of the rights issue’s total volume. Memorandum, teaser and subscription form are available on the websites of the company (www.expres2ionbio.com) and Sedermera Fondkommission (www.sedermera.se). Subscription through Bank-ID is also available at Sedermera Fondkommission’s website.
Hørsholm, Denmark, February 7th, 2018 – ExpreS2ion Biotech Holding AB (”ExpreS2ion”) hereby publishes its memorandum in Swedish and English in relation to the preferential rights issue, for which the subscription period starts on February 8th. 2018.
Hørsholm, Danmark, January 16, 2018 – ExpreS2ion Biotech Holding AB (”ExpreS2ion”) announces that the Board has decided, pursuant to the authorisation granted by an Extraordinary General Meeting, to carry out a preferential rights issue with the aim to accelerate the Company's development. The preferential rights issue comprises a maximum of 2,400,403 shares with a subscription price of 8.00 SEK per share. The public is also invited to subscribe for shares. Upon full subscription of the rights issue, Expres2ion will raise approximately MSEK 19,203,224 before issue expenses. Beforehand, ExpreS2ion has agreed on subscription commitments amounting to approximately MSEK 10.9, corresponding to approximately 57 percent of the total issue amount, with persons and entities including management, major shareholders and institutions. ExpreS2ion also announces that the Company's Year End Report will be published on February 7, 2018. The previous publication date was February 28, 2018. Notice of the Extraordinary General Meeting will be published shortly.
Hørsholm, Denmark, December 28, 2017 – Today, ExpreS2ion Biotech Holding AB and its affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announce that the company’s patent application “Improved Protein Expression System”, that covers the entire ExpreS2 platform, has been allowed in India and will be granted with expiry June 12, 2029.
Hørsholm, Denmark / Bilthoven, the Netherlands, December 11, 2017 – Today, ExpreS2ion Biotechnologies ApS (“ExpreS2ion”) and Intravacc (the Institute for Translational Vaccinology), announce the signing of a collaboration agreement. This agreement strengthens ExpreS2ion’s ability to service customers and partners across the full value chain of vaccine development and expands the commercial opportunities for both organisations. Under the agreement, Intravacc will serve as a preferred GMP (Good Manufacturing Practice) partner for ExpreS2ion. The agreement contains no financial exchange between ExpreS2ion and Intravacc. However, it expands the commercial opportunities in the vaccine field for both organisations.
Hørsholm, Denmark, December 4, 2017 – Today, ExpreS2ion Biotech Holding AB announces that the fully owned subsidiary ExpreS2ion Biotechnologies ApS (“ExpreS2ion”) has entered a collaboration with the Germany based Institut Virion\Serion GmbH (“Virion”). Virion is granted access to evaluate a number of new in vitro diagnostic product candidates, as well as commercial rights to promote, sell and distribute protein antigens produced using ExpreS2. The financial terms of the agreements are not disclosed, but ExpreS2ion expects to generate annual revenues in excess of 250,000 EUR as a result of these agreements, when the collaboration is implemented.
Hørsholm, Denmark, 28 November 2017 – Today, ExpreS2ion Biotech Holding AB announces that the fully owned subsidiary ExpreS2ion Biotechnologies ApS (“ExpreS2ion”)’s 50% owned joint venture, AdaptVac’s, scientific paper presenting proof of concept in animals (POCA) for its novel breast cancer vaccine candidate, AV001, will be published in the peer reviewed scientific journal ‘OncoImmunology’. The results demonstrate that AV001 is effective for both prevention and therapy of breast cancer in an advanced mouse model.
Horsholm, Denmark, November 8, 2017 – Today, ExpreS2ion Biotechnologies ApS (“ExpreS2ion”), a fully owned subsidiary of ExpreS2ion Biotech Holding AB, announces that University of Pennsylvania, Philadelphia, USA, has signed a Research License Agreement granting University of Pennsylvania the right to conduct research using ExpreS2ion’s proprietary protein expression system, ExpreS2.
Hørsholm, Denmark, October 18, 2017 – Today, ExpreS2ion Biotech Holding AB (“ExpreS2ion”) announces that its joint venture, AdaptVac ApS (“AdaptVac”), has reached proof of concept in advanced animal models (POCA) for AV-001, its novel vaccine treatment against breast cancer tumours. This is a significant milestone for AdaptVac in the progress towards clinical development. AdaptVac will now initiate discussions with large pharmaceutical companies regarding a license or collaboration agreement for the clinical development of the project.
Hørsholm, Denmark, October 2, 2017 – Today, ExpreS2ion Biotech Holding AB announces that the fully owned subsidiary ExpreS2ion Biotechnologies ApS (“ExpreS2ion”) and NextGen Vaccines ApS (“NextGen”) have finalised all agreements for the AdaptVac ApS (“AdaptVac”) joint venture following the successful share issue in August 2017. In addition, ExpreS2ion expects AdaptVac to release additional information on animal data and its primary breast cancer vaccine candidate within the following weeks.
In August 2017, ExpreS2ion Biotech Holding AB (”ExpreS2ion”) conducted a rights issue of shares in which the public was also invited to subscribe for shares. Through the rights issue, 872 873 new shares were issued. The last day of trading in BTA (“Betald tecknad aktie”) is September 21, 2017 and the stop day is September 25, 2017.
On 24 August 2017, the subscription period of ExpreS2ion Biotech Holding AB's ("ExpreS2ions") rights issue with a maximum of approx. SEK 3.9 million ended. The rights issue was subscribed at approx. SEK 6 million, corresponding to a subscription rate of approximately 153 percent. Through the rights issue, 872,873 new shares are issued and ExpreS2ion receives approx. SEK 3.9 million before the emission costs of approx. SEK 0.4 million. Settlement notes are due to be sent out today, 30 August, 2017. Note: This is a non-certified English translation of a press release originally drafted in Swedish and published 08:32 CET, 30 August 2017. The Swedish version prevails.
Today, on August 10th 2017, the subscription period in ExpreS2ion Biotech Holding AB’s (”ExpreS2ion”) rights issue of shares is initiated. The subscription period ends on August 24th 2017. A fully subscribed rights issue provides ExpreS2ion approximately SEK 3.9 million before issuing costs. Beforehand, the company has agreed on subscription commitments amounting to approximately SEK 2.2 million, which equals to approximately 57 percent of the rights issue’s total volume. Memorandum, teaser and subscription form are available on the website of the company (www.expres2ionbio.com) and the website of Sedermera Fondkommission (www.sedermera.se).
Hørsholm, Denmark, July 17, 2017 – Today, ExpreS2ion Biotech Holding AB announces that the fully owned subsidiary ExpreS2ion Biotechnologies ApS (“ExpreS2ion”) has entered a Master Services Agreement and a Research & Commercial License Agreement with the US based Integrated BioTherapeutics, Inc. (“IBT”). The agreements enable standardised activation of a range of services and products from ExpreS2ion. This primarily targets the development and manufacturing of proteins based on the ExpreS2 platform, as well as granting IBT commercial rights to promote, sell and distribute such protein products made with ExpreS2. IBT expects to expand their unique research protein portfolio annually with up to five protein antigens manufactured in ExpreS2. ExpreS2ion and IBT do not disclose the financial terms of the agreements, which constitutes a part of both companies’ general business models, however, when the collaboration is fully implemented, ExpreS2ion expects to generate annual revenues of up to 1.0 million SEK as a result of these agreements.
Horsholm, Denmark, July 5, 2017 – Today, ExpreS2ion Biotech Holding AB announces that the Jenner Institute of the University of Oxford, a licensee of the fully owned subsidiary ExpreS2ion Biotechnologies ApS (“ExpreS2ion”), initiates recruiting for a Phase IIa clinical trial following a successful Phase I safety study of its new blood stage malaria vaccine. The Phase IIa trial will assess safety, immunogenicity and efficacy of the blood-stage malaria vaccine, which is produced in ExpreS2ion’s proprietary platform, Expres2. Malaria is causing more than 400,000 deaths annually, and the vaccine addresses a global market estimated by The Boston Consulting Group to be in the size of up to $400M per year.
Hørsholm, Denmark, June 28, 2017 – Today, ExpreS2ion Biotech Holding AB announces that the fully owned subsidiary ExpreS2ion Biotechnologies ApS (“ExpreS2ion”) via its ownership in AdaptVac ApS (“AdaptVac”) and the proprietary new Plug-and-Play Virus-Like Particle (VLP) technology, has accelerated the development of efficient therapeutic and prophylactic vaccines within high value segments of oncology, infectious diseases and immunological disorders. This represents a new market focus for ExpreS2ion and a strong repositioning potential due to the shift from being mainly a service provider to also being a developer of vaccines. The risk-adjusted net present value of ExpreS2ion’s stake in AdaptVac’s initial pipeline is estimated to be in the 50-100 million SEK range.
Hørsholm, Denmark, June 21, 2017 – Today, ExpreS2ion Biotech Holding AB announces that the fully owned subsidiary ExpreS2ion Biotechnologies ApS (“ExpreS2ion”) has established a joint venture named AdaptVac ApS with NextGen Vaccines ApS (“NextGen”), a company recently formed by scientists from the University of Copenhagen. AdaptVac has a worldwide exclusive license to a new Plug-and-Play Virus Like Particle (VLP) technology, which enables accelerated development of efficient therapeutic and prophylactic vaccines within high value segments of oncology, infectious diseases and immunological disorders.
Horsholm, Denmark, April 20, 2017 – Today, ExpreS2ion Biotech Holding AB (“ExpreS2ion”), announces that the fully owned subsidiary ExpreS2ion Biotechnologies ApS has entered into a non-exclusive license agreement with ABIVAX S.A. for the commercial use of ExpreS2ion’s expression system, ExpreS2, for their ABX544 Ebola program. The financial terms of the agreement are not disclosed. The agreement follows the term sheet announcement, which ExpreS2ion communicated in a press release on December 12, 2016.
Horsholm, Denmark, April 6, 2017 – Today, ExpreS2ion Biotech Holding AB (“ExpreS2ion”), announces that the fully owned subsidiary ExpreS2ion Biotechnologies ApS has filed a joint patent application for an improved blood-stage malaria vaccine together with the Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia. This patent positions ExpreS2ion and the Walter and Eliza Hall Institute well for future development of this promising vaccine, addressing a large market with unmet needs. Under a joint vaccine development and patent sharing agreement between ExpreS2ion and The Walter and Eliza Hall Institute, the parties co-own the joint-patent equally.
Horsholm, Denmark, March 30, 2017 – Today, ExpreS2ion Biotechnologies ApS (“ExpreS2ion”), a fully owned subsidiary of ExpreS2ion Biotech Holding AB, announces the final approval of a Consortium Agreement together with Abera Bioscience AB and the University of Copenhagen, for a Eurostars grant for the project named ‘OptiFemVac’. The approval of the Consortium Agreement triggers a grant of approx. EUR 750,000 of which ExpreS2ion expects to receive approx. EUR 300,000. The approval follows the initial approval which ExpreS2ion Biotech Holding AB communicated in a press release on January 23, 2017.
Horsholm, Denmark, February 16, 2017 – Today, ExpreS2ion Biotechnologies ApS (“ExpreS2ion”), a fully owned subsidiary of ExpreS2ion Biotech Holding AB, announces that its Chief Scientific Officer, Dr. Willem Adriaan (“Wian”) de Jongh, is speaking at the ISBiotech 7th Spring Meeting in Washington D.C., USA, on March 6th, 2017, presenting under the headline “Development of Malaria Sub-Unit Vaccines Using the Non-Viral Drosophila S2 Insect Cell Expression System”.
Horsholm, Denmark, February 14, 2017 – Today, ExpreS2ion Biotechnologies ApS (“ExpreS2ion”), a fully owned subsidiary of ExpreS2ion Biotech Holding AB, announces that its Chief Scientific Officer, Dr. Willem Adriaan (“Wian”) de Jongh, is appointed the honorary position of affiliated associate professor at the Technical University of Denmark (“DTU”). The position is for a duration of five years, commencing in February 2017.